7th Eurasian Hematology Oncology Summit
E

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
December 11, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…

04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Tri…

15:12
Yale Cancer Center

ASH 2021: Cellular Therapies in Myeloma

Feat. N. Bar
22:41
Ehsan Malek

Importance and Prospect of Maintenance Treatment in Post-SCT MM Pati…

26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer
13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patient…

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Di…

Feat. K. Maples
27:42
2021 Virtual KU Hematology and Medical Oncology Review

CAR T-Cell and CRISPR in Hematologic Malignancies: Continuing Revolu…

Feat. J. McGuirk
31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Future P…

Feat. M. Alsina
22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Disc…

Feat. M. Leukam
17:44
UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytok…

Feat. S. Kosuri
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myel…

10:47
SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly D…

Feat. S. Lonial
13:12
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Addressing Current Questions and Controversies in the Mana…

Feat. M. Gertz